Company intelligence / Profile preview

Aegle HCS

Miami, Florida, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

AGLE‑102, the lead candidate, is in a Phase 1/2 clinical trial for recessive dystrophic epidermolysis bullosa. Preclinical data show that AGLE‑102 can induce COL7 production and deliver COL7 protein to deficient fibroblasts, with potential benefits including reduced inflammation, enhanced healing, and improved tissue regeneration. Other programs are at preclinical stage targeting burns and graft vs. host disease. No published late-stage or commercial results yet.

Therapeutic areas: ImmunologyDermatologyRare Diseases
Modalities: Extracellular vesicle therapyExosome-based therapyBiologic
Industry: Biotech

Partnerships

University of Miami [exclusive license on EV harvesting technology ]

Beyond the preview

Go deeper on Aegle HCS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aegle HCS.

Explore the full profile